Association between survivin gene promoter-31G/C and-644C/T polymorphisms and non-small cell lung cancer

被引:16
|
作者
Aynaci, E. [1 ]
Coskunpinar, E. [2 ]
Eren, A. [2 ]
Kum, O. [1 ]
Oltulu, Y. M. [2 ]
Akkaya, N. [2 ]
Turna, A. [3 ]
Yaylim, I. [2 ]
Yildiz, P. [1 ]
机构
[1] Yedikule Chest Dis & Thorac Surg Training & Res H, Istanbul, Turkey
[2] Istanbul Univ, Inst Expt Med, Dept Mol Med, Istanbul, Turkey
[3] Istanbul Univ, Cerrahpasa Med Fac, Dept Thorac Surg, Istanbul, Turkey
关键词
Non-small cell lung cancer; Survivin; Gene polymorphism; Genetics; Biomarker; THERAPEUTIC TARGET; MESSENGER-RNA; RISK; EXPRESSION; CARCINOMA; INHIBITOR;
D O I
10.4238/2013.February.28.9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Lung cancer is the most common cancer worldwide. Survivin is one of the first reported inhibitors of apoptosis proteins, which is an important family of proteins that regulate apoptosis. The survivin gene is located on human chromosome 17q25, which is composed of 142 amino acids. A common polymorphism of the survivin gene promoter -31G/C has been shown to influence cancer risk. This genetic variant has been associated with overexpression of survivin at both protein and mRNA levels in cancer cells. We examined promoter (-31G/C) genotype frequency in a patient group (N = 146), 77.4% GG, 18.5% GC, 4.1% CC, and in a control group (N = 98), 57.1% GG, 34.7% GC, 8.2% CC. These distributions were significantly different. Promoter (-644C/T) genotype frequency in the patient group was 40.4% TT, 48.6% TC, 11% CC, and in the control group it was 55.1% TT, 40.8% TC, 4.1% CC; these distributions were also significantly different. Individuals carrying the survivin 31 GC genotype and those carrying the survivin 644 CC genotype had a significantly decreased risk of having non-small cell lung cancer.
引用
收藏
页码:3975 / 3982
页数:8
相关论文
共 50 条
  • [31] Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC)
    Aynaci, Engin
    Coskunpinar, Ender
    Eren, Ayse
    Kum, Onur
    Oltulu, Yasemin Musteri
    Akkaya, Nergiz
    Turna, Akif
    Aynaci, Aysun
    Yaylim, Ilhan
    Yildiz, Pinar
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [32] Association between MGMT Promoter Methylation and Non-Small Cell Lung Cancer: A Meta-Analysis
    Gu, Changmei
    Lu, Jiachun
    Cui, Tianpen
    Lu, Cheng
    Shi, Hao
    Xu, Wenmao
    Yuan, Xueli
    Yang, Xiaobo
    Huang, Yangxin
    Lu, Meixia
    PLOS ONE, 2013, 8 (09):
  • [33] RETRACTED: Association between polymorphisms in the XRCC1 gene and the risk of non-small cell lung cancer (Retracted Article)
    Han, J. C.
    Zhang, Y. J.
    Li, X. D.
    GENETICS AND MOLECULAR RESEARCH, 2015, 14 (04): : 12888 - 12893
  • [34] Chemokines, Their Gene Polymorphisms in Resectable Non-Small Cell Lung Cancer (NSCLC)
    Drosslerova, M.
    Sterclova, M.
    Vasakova, M.
    Taskova, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [35] The association between the survivin-31G/C promoter polymorphism and hepatocellular carcinoma risk in a Turkish population
    Bayram, Suleyman
    Akkiz, Hikmet
    Bekar, Aynur
    Akgollu, Ersin
    CANCER EPIDEMIOLOGY, 2011, 35 (06) : 555 - 559
  • [36] Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer
    Dong Jie
    Wang Xu
    Yu Yu
    Yan Xu
    Cui Jiu-Wei
    中华医学杂志英文版, 2018, 131 (16) : 1904 - 1908
  • [37] Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
    Alessandro Di Federico
    Ilaria Ricciotti
    Valentina Favorito
    Sandra Vietti Michelina
    Pietro Scaparone
    Giulio Metro
    Andrea De Giglio
    Federica Pecci
    Giuseppe Lamberti
    Chiara Ambrogio
    Biagio Ricciuti
    Current Oncology Reports, 2023, 25 : 1017 - 1029
  • [38] Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer
    Dong, Jie
    Wang, Xu
    Yu, Yu
    Yan, Xu
    Cui, Jiu-Wei
    CHINESE MEDICAL JOURNAL, 2018, 131 (16) : 1904 - 1908
  • [39] Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
    Di Federico, Alessandro
    Ricciotti, Ilaria
    Favorito, Valentina
    Michelina, Sandra Vietti
    Scaparone, Pietro
    Metro, Giulio
    De Giglio, Andrea
    Pecci, Federica
    Lamberti, Giuseppe
    Ambrogio, Chiara
    Ricciuti, Biagio
    CURRENT ONCOLOGY REPORTS, 2023, 25 (09) : 1017 - 1029
  • [40] Differences on immune biomarkers between KRAS G12C and KRAS non-G12C mutated non-small cell lung cancer
    Pinto, L. Masfarre
    Parreira, A. S. D. F. M.
    Unanua, N. Castro
    Rocha, P.
    Ruiz, I. Morilla
    Sanchez, L. Teijeira
    Clave, S.
    Gorro, N. Navarro
    Mora, R. Bach
    Sanchez, I.
    Campos, M. A. Galindo
    Garcia, A. Taus
    Martinez, A. Azkarate
    Fabregat, R. Marse
    Paricio, B. Bellosillo
    Arasanz, H.
    Aguillo, M. Martinez
    Arriola, E.
    ANNALS OF ONCOLOGY, 2023, 34